[Human monoclonal antibodies to HIV-1 infection].
HIV-1, which causes AIDS, has infected over 50 million and killed over 20 million individuals world wide since the beginning of the epidemic two decades ago. The introduction of highly active anti-retroviral therapy(HAART) has resulted in the control of the disease progression. Furthermore, supervised treatment interruption(STI) of HAART might be expected significantly to boost immune function and slow the progression of AIDS. On the other hand, several combinations of human monoclonal antibodies(hu-mo-Ab) against HIV-1 has been identified, and demonstrates the efficacy of the triple combination of hu-mo-Ab with neutralizing activity in macaque model. Therefore, a combination of chemotherapy and immunotherapy, such as hu-mo-Ab will be prove to be the most effective route for HIV-1 therapy.
Kawai
Masahiro
M
Department of Molecular Biology, Nagoya City University School of Medicine.
Okada
Noriko
N
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000914:Antibodies, Viral / Q000627:therapeutic use*; D015693:Gene Products, nef / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D015700:HIV Envelope Protein gp41 / Q000276:immunology; D015658:HIV Infections / Q000628:therapy*; D015497:HIV-1; D006801:Humans; D008251:Macaca; D054311:nef Gene Products, Human Immunodeficiency Virus
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D015693:Gene Products, nef; D015699:HIV Envelope Protein gp120; D015700:HIV Envelope Protein gp41; D054311:nef Gene Products, Human Immunodeficiency Virus